CClinicalTrials.gg
Active, not recruitingNCT05876533Updated Dec 31, 2024

R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances

An observational study in Chronic Heart Failure, sponsored by Cordio Medical. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Cordio Medical · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
216
Ages
22 Years and older
Sex
All
01

Study summary

To determine the usability and technical aspects of Cordio HearO™

Read the detailed description

The system (including App and server) will be tested under simulated use conditions with representative users to identify potential changes required to the application user interface, to improve user performance and satisfaction, and to inform future design options.

The recordings data will also be used for algorithm improvement

02

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • CHF
03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult clinical stable patients with NYHA II-IVa (ambulatory)

Eligibility criteria

Major inclusion Criteria:

  1. Adults patients
  2. Diagnosed with Symptomatic Chronic Heart Failure [NYHA II-IVa (ambulatory)]
  3. At least one of the following:

    1. One ADHF hospitalization in the last 12 months
    2. One unplanned IV/SC diuretic administration in the last 6 months
    3. Two unplanned IV/SC diuretic administration in the last 12 months
    4. NTProBNP >500 pg/ml or BNP*> 150 pg/ml at screening visit
  4. Clinically stable HF
  5. Willing to participate as evidenced by signing the written informed consent.
  6. Male or non-pregnant female patient (pre-menopausal women will confirm verbally).

Major exclusion Criteria:

  1. Not able to read in Hebrew, Russian, Arabic, English and/or Spanish.
  2. Unable to comply with daily use of the App
  3. Major cardiovascular event
  4. Had a Cardiac Resynchronization Device (CRT) implanted or upgrading ≤ 1 month prior to screening visit.
  5. Has estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 meter square (Cockroft-Gault formula).
  6. Is likely to undergo heart transplantation/ LVAD within 6 months of Screening Visit.
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
216 participants (actual)
Patient registry
No

Interventions

  • DeviceCordio HearO

    Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or "app") that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients

05

What researchers measure

Primary outcomes

  1. Patient Usability success defined as: 1.Total and individual usability score of ≥3 in the usability questionnaire in ≥80% of the users.

    The used scale is: Usability questionnaire for the Cordio HearO™ App. This Usability questionnaire is a subjective evaluation based on Likert score of device user satisfaction. Maximum value for each item: 5 Minimum value for each item: 1 Higher scores means a better outcome

    Time frame: 2 years

  2. Patient Usability success defined as: 2. Total Compliance

    The total compliance will be determined by the total number of recording days. Success will be considered if total average compliance of 70 % of all days.

    Time frame: 2 Years

06

Study locations

8 sites
  • Kurker Family Medicine
    South Windsor, Connecticut 06074, United States
  • C&R Research Services
    Cape Coral, Florida 33904, United States
  • C&R Research Services
    Miami, Florida 33176, United States
  • C&R Research Services
    Miami, Florida 33183, United States
  • Lake County Med Grp
    Athens, Georgia 31024, United States
  • Barzilai Medical Center- Cardiology
    Ashkelon, Israel
  • Heart Failure Clinic - Clallit Be'er Sheva
    Be'er Sheva, Israel
  • Rabin Medical Center - Cardiology- CHF
    Petah tikva, 49100, Israel
07

Registry details

Key details

Study ID
NCT05876533
Lead sponsor
Cordio Medical
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Mar 18, 2022
Primary completion
Jan 31, 2025 (estimated)
Completion
Mar 15, 2025 (estimated)
Last update
Dec 31, 2024

Study contacts

Ronit Haviv, PhD
study director · Cordio Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion